BCL2L11 Antibody

What applications are BCL2L11 antibodies validated for in research?

BCL2L11 antibodies are validated for multiple applications, with specific utility dependent on the particular antibody clone and manufacturer. Based on the search results, most commercially available BCL2L11 antibodies are validated for:

• Western Blot (WB): Generally at dilutions of 1:500-1:2000

• Immunohistochemistry (IHC): Typically at dilutions of 1:50-1:500

• Immunocytochemistry (ICC): Often at 2.5-10 μg/mL

• Immunofluorescence (IF): Usually at 1:100-20 μg/mL

• ELISA: Dilutions vary by manufacturer

• Immunoprecipitation (IP): Selected antibodies only

Detailed validation data is typically provided by manufacturers, such as the Western blot analysis shown for K562 cell lysates with specific BCL2L11 antibodies at 1-2 μg/mL concentrations . When selecting an antibody, researchers should review validation images for their specific application and cell/tissue type of interest.

What is the molecular weight of BCL2L11 and why does it sometimes appear different on Western blots?

This discrepancy occurs due to:

• Multiple isoforms: BCL2L11 exists in several isoforms (BIM EL, BIM L, BIM S), with BIM EL being the longest

• Post-translational modifications: Phosphorylation and other modifications can alter migration patterns

• Antibody specificity: Some antibodies detect only specific isoforms (e.g., "This antibody only detects the Bim EL isoform")

Researchers should be aware of which isoform(s) their selected antibody detects when interpreting results .

How should BCL2L11 antibodies be stored for optimal performance?

Proper storage is critical for maintaining antibody efficacy. Based on manufacturer recommendations:

• Short-term storage (up to three months): 4°C

• Long-term storage (up to one year): -20°C

• Avoid repeated freeze-thaw cycles as noted by several suppliers

• Most BCL2L11 antibodies are supplied in PBS containing 0.02% sodium azide and often 50% glycerol at pH 7.3-7.4

Some manufacturers specifically note that "Antibodies should not be exposed to prolonged high temperatures" . Aliquoting may be recommended for antibodies not containing glycerol to minimize freeze-thaw cycles.

What controls should be used when validating BCL2L11 antibody specificity?

Proper controls are essential for confirming antibody specificity:

Positive Controls:

• Cell lines with confirmed BCL2L11 expression: K562 cells, RAW 264.7 cells, and Raji cells are frequently used

• Tissues: Human breast cancer tissue and human prostate cancer tissue show positive IHC staining

Negative Controls:

• BCL2L11 knockout or knockdown cells/tissues

• Blocking peptides: Many suppliers offer peptides corresponding to the immunogen region (e.g., "Blocking peptide can be purchased")

• Isotype control: Rabbit IgG at equivalent concentration for most polyclonal antibodies

Specificity Testing:

• Multiple isoform detection: Verify which isoforms (BIM EL, BIM L, BIM S) your antibody detects

• Cross-reactivity assessment: Test against other BCL-2 family members, especially if studying protein-protein interactions

What are the recommended dilutions and protocols for Western blot analysis of BCL2L11?

Western blot optimization for BCL2L11 detection requires careful consideration:

Sample Preparation:

• Cell lysates: K562, RAW 264.7, or Raji cells are commonly used

• Tissue extracts: Mouse eye tissue has been validated

Recommended Dilutions:

• Boster Bio antibody: 1-2 μg/mL

• Proteintech antibody: 1:500-1:1000

• Specifics vary by manufacturer and should be optimized

Protocol Notes:

• Use fresh samples whenever possible

• Include protease inhibitors in lysis buffer

• Run appropriate molecular weight markers (observe for bands at approximately 23-68 kDa depending on isoform)

• For transfer, use PVDF membrane (preferred over nitrocellulose for many BCL2L11 antibodies)

• Block with 5% non-fat milk or BSA (check manufacturer recommendations)

• Incubate with primary antibody overnight at 4°C

• Use appropriate secondary antibody (typically anti-rabbit IgG-HRP for most BCL2L11 antibodies)

A detailed Western blot protocol is often available from the manufacturer and should be consulted for specific antibodies .

How can BCL2L11 antibodies be used to study the role of this protein in cancer therapy resistance?

BCL2L11 has emerged as a critical factor in cancer therapy resistance, particularly in targeted therapies. Research applications include:

Mechanistic Studies:

• BCL2L11 expression correlates with sensitivity to combined Src and MEK1/2 inhibitors in thyroid cancer

• The induction of BCL2L11 after treatment can serve as a biomarker for drug sensitivity

Experimental Approaches:

• Expression Analysis: Monitor BCL2L11 protein levels before and after drug treatment using Western blot

• Pathway Analysis: Combine with antibodies against phosphorylated FAK/Src, MEK/ERK, and AKT to correlate pathway inhibition with BCL2L11 induction

• Functional Studies: Pair with apoptosis assays to link BCL2L11 upregulation to cell death

Research Finding Example:
"Cells that are sensitive to combined dasatinib and trametinib treatment have inhibition of FAK/Src, MEK/ERK, and AKT, resulting in the dramatic upregulation of BIM, while cells that are resistant lack inhibition of AKT and have a dampened induction of BIM" .

This approach helps identify mechanisms of drug resistance and potential combination strategies to overcome it, such as combining dasatinib/trametinib with BCL-XL inhibitors in resistant cells .

How do epigenetic modifications regulate BCL2L11 expression, and how can this be studied?

BCL2L11 expression is tightly regulated by epigenetic mechanisms, which has implications for both normal development and disease:

Epigenetic Regulation Mechanisms:

• Histone Modifications:

  • H3K27me3 (repressive mark) enrichment at BCL2L11 promoter in certain cell types

  • H3K4me2/me3 modifications associated with "poised" gene status

  • H3K27ac at enhancer regions correlates with active transcription

• Long-range Chromatin Interactions:

  • "BCL2L11 silencing by EBV has only been studied in the context of EBNA3A and EBNA3C binding to the gene promoter"

  • "Inactivation of a murine-specific BCL2L11 enhancer has recently been reported in B lymphoblastic leukaemia"

Experimental Approaches:

• ChIP-qPCR: To analyze histone modifications at the BCL2L11 promoter and enhancers

  • "Assessment of epigenetic marks in these regions revealed an enrichment of the repressive mark H3K27me3 at the promoter of BCL2L11 gene in mature T-ALL"

• 3C Analysis: To study long-range chromosomal interactions

  • "3C analysis in BL31 cells to examine BCL2L11 promoter interactions with additional intervening control regions"

• Drug Studies: Using epigenetic modifiers to alter BCL2L11 expression

  • "Treatment with LSD1i (particularly with the steric inhibitor SP2509) restored the expression of ZEB2/LSD1 pro-apoptotic BIM (BCL2L11) target"

This research is particularly relevant in cancer contexts, where epigenetic silencing of BCL2L11 may contribute to therapy resistance.

What methodological approaches can be used to study BCL2L11 interactions with other Bcl-2 family proteins?

Studying BCL2L11 interactions with other Bcl-2 family members requires specialized techniques:

Protein-Protein Interaction Methods:

• Co-Immunoprecipitation (Co-IP):

  • Use BCL2L11 antibodies validated for immunoprecipitation

  • Pull down BCL2L11 and probe for interacting partners (Bcl-2, Bcl-xL, Bcl-w)

  • Reciprocal IP can confirm interactions

• Proximity Ligation Assay (PLA):

  • Allows visualization of protein interactions in situ

  • Requires antibodies raised in different species for BCL2L11 and its binding partners

• FRET/BRET Analysis:

  • For studying dynamic interactions in living cells

  • Requires fluorescent or bioluminescent tagging of proteins

Research Context:
"Bim/BOD interacts with diverse members in the pro-survival Bcl-2 sub-family including Bcl-2, Bcl-xL and Bcl-w. Bim/BOD induces apoptosis."

Technical Considerations:

• Use antibodies targeting different epitopes to avoid competition for binding sites

• Consider isoform-specific interactions (BIM EL may have different binding partners than BIM S)

• Control for detergent effects which may disrupt hydrophobic interactions

• Validate antibody specificity to avoid cross-reactivity with other BH3-only proteins

Why might BCL2L11 antibody staining patterns differ between applications and cell types?

Differences in BCL2L11 staining patterns can occur due to multiple factors:

Application-Specific Factors:

• Fixation Effects:

  • Formalin fixation for IHC may mask epitopes

  • Different fixatives (PFA vs. methanol) can affect antibody accessibility

  • "Suggested antigen retrieval with TE buffer pH 9.0; Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0"

• Subcellular Localization:

  • BCL2L11 primarily localizes to mitochondria but may show different distributions depending on activation state

  • In ICC/IF, patterns may range from diffuse cytoplasmic to punctate mitochondrial

• Isoform Expression:

  • "Multiple isoforms of Bim are known to exist; this antibody only detects the Bim EL isoform"

  • Different cell types may express varying ratios of isoforms

Cell Type Considerations:

• Expression Levels:

  • BCL2L11 expression varies widely between tissues and cell types

  • "The messenger RNA of Bim is ubiquitously expressed in multiple tissues and cell lines"

• Post-translational Modifications:

  • Phosphorylation status varies by cell type and treatment condition

  • May affect antibody recognition and apparent molecular weight

• Complexes with Other Proteins:

  • Interaction with other Bcl-2 family members may mask epitopes

  • "Bcl2 family members form hetero- or homodimers"

Methodological Solutions:

• Test multiple antibodies targeting different epitopes

• Include positive control samples with known BCL2L11 expression

• When comparing cell types, normalize to loading controls and consider relative expression

How can researchers optimize BCL2L11 antibody-based detection in samples with low expression levels?

Detecting low levels of BCL2L11 requires special consideration:

Sample Preparation Strategies:

• Enrichment Methods:

  • Mitochondrial fractionation to concentrate BCL2L11 protein

  • Immunoprecipitation before Western blot analysis

• Protein Stabilization:

  • Use of proteasome inhibitors (BCL2L11 has rapid turnover)

  • Apoptosis inducers to upregulate BCL2L11 as positive controls

Signal Amplification Techniques:

• For Western Blot:

  • Extended exposure times with high-sensitivity chemiluminescent substrates

  • Load more protein (up to 100 μg per lane)

  • Use PVDF membrane instead of nitrocellulose for better protein retention

• For IHC/ICC:

  • Tyramide signal amplification (TSA) systems

  • Polymer-based detection systems instead of standard ABC method

  • Extended primary antibody incubation (overnight at 4°C)

• For Flow Cytometry:

  • Intracellular staining after fixation and permeabilization

  • Use of fluorochromes with higher quantum yield

Optimization Guidelines:

• Titrate antibody concentrations to find optimal signal-to-noise ratio

• Extend incubation times while reducing temperature

• Reduce washing stringency (fewer washes, gentler buffers)

• Use signal enhancers appropriate for your detection method

By implementing these strategies, researchers can successfully detect low-abundance BCL2L11 protein while maintaining specificity.

How does BCL2L11 function in normal B-cell immune responses and lymphoid malignancies?

BCL2L11 plays a crucial role in regulating B-cell homeostasis and is frequently dysregulated in lymphoid malignancies:

Normal B-cell Function:

• BCL2L11 is essential for developmentally programmed lymphocyte death

• "Upon immunization with the model antigen NP-KLH, bcl-2 transgenic mice accumulate in their spleens abnormally increased numbers of antigen-specific B cells"

• BCL2L11 helps eliminate B cells expressing low-affinity antigen receptors that cannot compete effectively for survival signals

Role in Lymphoid Malignancies:

• Epstein-Barr Virus (EBV) Infection:

  • "EBV EBNA2 upregulates MYC and inactivates BCL2L11"

  • "EBNA3A and EBNA3C binding to the gene promoter" leads to BCL2L11 silencing

• B Lymphoblastic Leukemia:

  • "Inactivation of a murine-specific BCL2L11 enhancer has recently been reported in B lymphoblastic leukaemia"

  • Loss of BCL2L11 contributes to resistance to apoptosis

• T-ALL (T-cell Acute Lymphoblastic Leukemia):

  • "The pro-apoptotic BCL2L11 (BIM) is significantly lower in expression in ETP-ALL samples compared to mature T-ALL"

  • "The repression of BCL2L11 (BIM) expression is ensured by the EZH2/PRC2 complex through the transcription factor HES1"

Therapeutic Implications:
"The therapeutic strategy of reactivating the expression of BCL2L11 (BIM) in cancer cells, in order to induce their apoptosis, has been explored for decades"

This fundamental understanding of BCL2L11's role informs therapeutic approaches targeting apoptotic pathways in lymphoid malignancies.

What is the significance of BCL2L11 in combination therapy approaches for cancer treatment?

BCL2L11 has emerged as a critical mediator of response to combination therapies:

Mechanistic Significance:

• Convergence Point of Multiple Pathways:

  • "BIM is a convergent point of the Src and MAPK pathways for the regulation of growth and apoptosis"

  • Acts as a node integrating signals from various oncogenic pathways

• Biomarker for Therapy Response:

  • BCL2L11 induction correlates with sensitivity to combined targeted therapies

  • "Cells that are sensitive to combined dasatinib and trametinib treatment have inhibition of FAK/Src, MEK/ERK, and AKT, resulting in the dramatic upregulation of BIM"

Combination Strategies:

• Targeting Upstream Regulators:

  • JAK/STAT inhibition (Ruxolitinib) decreases expression of anti-apoptotic BCL2

  • LSD1 inhibitors restore BCL2L11 expression

• Direct BCL2 Family Targeting:

  • "Targeting directly BCL2 protein with ABT-199 in combination with LSD1i phenocopied the effects obtained with JAKi in ETP-ALL"

  • BCL-XL inhibitors can compensate for lack of BCL2L11 induction in resistant cells

Clinical Applications:
"The combination of LSD1i with JAK/STAT pathway inhibitor (JAKi, Ruxolitinib) reversed efficiently the expression ratio of BCL2/BIM (anti-/pro-apoptotic) in human and mouse ETP-ALL. The synergy between LSD1i and JAKi was highly active to specifically compromise the growth and the viability of ETP-ALL in vitro and in vivo."

These findings highlight the potential of using BCL2L11 as both a biomarker and a therapeutic target in rational combination therapy approaches.

How might single-cell approaches enhance our understanding of BCL2L11 regulation and function?

Single-cell technologies offer new possibilities for studying BCL2L11 biology:

Single-Cell Protein Analysis:

• Mass Cytometry (CyTOF):

  • Simultaneously measure BCL2L11 along with multiple signaling pathway components

  • Correlate BCL2L11 levels with phosphorylation states of upstream regulators (ERK, AKT)

  • Detect heterogeneity in BCL2L11 expression within populations

• Single-Cell Western Blotting:

  • Quantify BCL2L11 isoform distributions at the single-cell level

  • Identify rare cell populations with unique BCL2L11 expression patterns

Single-Cell Genomic Approaches:

• scRNA-seq:

  • Profile transcriptional regulators of BCL2L11 across cell populations

  • Identify cell states associated with BCL2L11 expression changes

• scATAC-seq:

  • Map chromatin accessibility at BCL2L11 regulatory regions

  • Correlate with enhancer usage and transcription factor binding

Spatial Transcriptomics/Proteomics:

• Examine BCL2L11 expression in tissue context

• Correlate with microenvironmental factors influencing BCL2L11 regulation

These approaches could resolve current questions about:

• Cell-to-cell variability in BCL2L11 responses to therapy

• Spatial organization of BCL2L11 regulation in tissues

• Temporal dynamics of BCL2L11 expression during apoptosis induction

What are emerging approaches for studying BCL2L11 post-translational modifications?

Post-translational modifications (PTMs) of BCL2L11 critically regulate its function, and new methods are emerging to study these modifications:

Mass Spectrometry-Based Approaches:

• Targeted Proteomics:

  • Parallel reaction monitoring (PRM) to quantify specific phosphorylation sites

  • Multiple reaction monitoring (MRM) for absolute quantification of modified peptides

• Top-Down Proteomics:

  • Analysis of intact BCL2L11 protein to capture combinatorial PTM patterns

  • Identification of previously unknown modifications

Antibody-Based Methods:

• PTM-Specific Antibodies:

  • Development of antibodies against specific phosphorylated forms of BCL2L11

  • Multiplexed analysis of different modifications simultaneously

• Proximity Ligation Assays:

  • Detection of interactions between modified BCL2L11 and binding partners

  • Spatial resolution of where modified BCL2L11 localizes within cells

Functional Approaches:

• CRISPR-Based Strategies:

  • Generation of modification-specific mutations in endogenous BCL2L11

  • Assessment of functional consequences in apoptotic responses

• Optogenetic Control:

  • Light-inducible systems to trigger BCL2L11 modifications

  • Real-time monitoring of functional consequences

These approaches will advance our understanding of how PTMs regulate BCL2L11's apoptotic function and may reveal new therapeutic opportunities for modulating its activity in disease contexts.